Global Startups Insights
Lets your startup
Funding News, North Dakota, USA Startup Funding News

Sharp Biomedical Closes Pre-Seed Funding Led by Gener8tor

October 13, 2026
By
Loren Baker
Sharp Biomedical Closes Pre-Seed Funding Led by Gener8tor

Sharp Biomedical, a medical device startup focused on spinal care, has closed its pre-seed funding round led by gener8tor 1889, a North Dakota-based venture capital fund. The round also included investments from several physician angel investors. The company did not disclose the amount raised.

The new funding will support the development and testing of Sharp Biomedical’s first set of medical tools and implant systems designed for outpatient pain clinics. The company aims to make certain spinal care procedures more accessible to patients with early-to-mid-stage chronic pain.

Sharp Biomedical is developing simple, manual procedures that can be performed in outpatient facilities without requiring expensive robotics, major infrastructure investments or extensive operating times. Its approach is designed to help local clinics provide treatment options to patients earlier in their care journey.

The company is working closely with doctors to create tools that match the way they already work in the clinic. These tools are meant to solve problems when it comes to treating pain. By using big hospitals and complicated machines Sharp Biomedical wants to help clinics that see patients outside of hospitals offer more types of treatments.

Dr. Danny Neuman, an interventional pain specialist, medical staff president at Ascentist Healthcare and an advisor to Sharp Biomedical, said the company is addressing an important gap in the market through physician-led product development.

“While the industry is rightfully focused on remarkable advancements in robotics and complex technologies for late-stage spinal care, we see a massive unmet need earlier in the care continuum,” said Dan Newman, Founder and CEO of Sharp Biomedical. “We are thrilled to partner with gener8tor 1889 and our angel investors to finalize our development. This pre-seed funding allows us to empower physicians with simple, safe, and reliable procedures—giving clinics advanced intervention capabilities without the burden of massive capital demands.”

“Dan is an extremely impressive startup founder, and we have built a huge amount of conviction in him and the entire Sharp Biomedical team,” said Ben Stanley, Principal of gener8tor 1889. “Their mission to democratize access to spine care by empowering outpatient clinics with fast, safe, and reliable toolsets is a breath of fresh air in a highly complex industry. We look forward to both the profound impact this technology will have on patient care, along with their continued commitment to growing the North Dakota biotech ecosystem.”

With the -seed funding now in place Sharp Biomedical is ready to move forward with its testing protocols collect more input from doctors and get ready for the important regulatory steps that come next before launching its first device.

The company works on creating tools and implants for spinal care focusing on safe and simple procedures that can be done in outpatient settings. The companys long-term goal is to make it easier for people to get treatment for pain. The company wants to do this while cutting down on the need, for hospital equipment and complicated surgery systems.

Recommended Stories for You